Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + Hepzato
|
DCT68EA
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
ABIRATERONE + Hepzato
|
DC2D550
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
ABIRATERONE + Hepzato
|
DCKZJI3
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
ABIRATERONE + Hepzato
|
DCOHUTU
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ABIRATERONE + Hepzato
|
DC8Z9BE
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Amonafide + Hepzato
|
DC8B38X
|
Amonafide
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Amonafide + Hepzato
|
DC8E8SR
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Amonafide + Hepzato
|
DCFACQZ
|
Amonafide
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Amonafide + Hepzato
|
DCTTL43
|
Amonafide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Anastrozole + Hepzato
|
DCIVBVY
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Anastrozole + Hepzato
|
DC4PD82
|
Anastrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
BIO-300 + Hepzato
|
DC3AR63
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Bleomycin + Hepzato
|
DCAHHUO
|
Bleomycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Cabazitaxel + Hepzato
|
DCH821U
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Cabazitaxel + Hepzato
|
DC9TEAV
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Cabazitaxel + Hepzato
|
DCLCGKE
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Cabazitaxel + Hepzato
|
DC6H9ME
|
Cabazitaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Cabazitaxel + Hepzato
|
DCXH4PZ
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Cabazitaxel + Hepzato
|
DCMZ1AM
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Crizotinib + Hepzato
|
DCS4I3K
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Crizotinib + Hepzato
|
DCYHVUO
|
Crizotinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Crizotinib + Hepzato
|
DCBPIA8
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Crizotinib + Hepzato
|
DC2GJWD
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Crizotinib + Hepzato
|
DC9HQAY
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Crizotinib + Hepzato
|
DCLVNQV
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Dacarbazine + Hepzato
|
DC0MM4Y
|
Dacarbazine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Dacarbazine + Hepzato
|
DC4UVM8
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Dacarbazine + Hepzato
|
DCTZQ2O
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[2] |
|
Dacarbazine + Hepzato
|
DCN6ELJ
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Dactinomycin + Hepzato
|
DCL8G6E
|
Dactinomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Dactinomycin + Hepzato
|
DC6E3CT
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Dactinomycin + Hepzato
|
DCZ3YOE
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Dactinomycin + Hepzato
|
DC69BZF
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Dactinomycin + Hepzato
|
DC11S14
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Dactinomycin + Hepzato
|
DCCH1Y1
|
Dactinomycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Dactinomycin + Hepzato
|
DCX8B7Q
|
Dactinomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Dactinomycin + Hepzato
|
DCSV9A6
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Dexrazoxane + Hepzato
|
DCTCEUM
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Dexrazoxane + Hepzato
|
DC0AG9C
|
Dexrazoxane
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Dexrazoxane + Hepzato
|
DCERJ1Z
|
Dexrazoxane
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Dexrazoxane + Hepzato
|
DCPAZ43
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Dexrazoxane + Hepzato
|
DCL23F7
|
Dexrazoxane
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Dexrazoxane + Hepzato
|
DCPHNN9
|
Dexrazoxane
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
DFN-15 + Hepzato
|
DCOM1GF
|
DFN-15
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
DFN-15 + Hepzato
|
DC6352A
|
DFN-15
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
DFN-15 + Hepzato
|
DC52MGE
|
DFN-15
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
DFN-15 + Hepzato
|
DCAAE55
|
DFN-15
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Digitoxin + Hepzato
|
DCGC62M
|
Digitoxin
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Epirubicin + Hepzato
|
DCC555H
|
Epirubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Epirubicin + Hepzato
|
DC7ZCA6
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Epirubicin + Hepzato
|
DC4GEG7
|
Epirubicin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Epirubicin + Hepzato
|
DCPREJV
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Epirubicin + Hepzato
|
DCQQDH3
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Epirubicin + Hepzato
|
DCM4RB6
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Epirubicin + Hepzato
|
DC2HZPI
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Epirubicin + Hepzato
|
DC21K16
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Epirubicin + Hepzato
|
DCFUUU0
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Epirubicin + Hepzato
|
DCACU1H
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Epirubicin + Hepzato
|
DCB19MS
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Epirubicin + Hepzato
|
DCS4NFC
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Epirubicin + Hepzato
|
DC75D1Y
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Epirubicin + Hepzato
|
DC8KU8I
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Estramustine + Hepzato
|
DCCIY7T
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Estramustine + Hepzato
|
DCBLO78
|
Estramustine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Estramustine + Hepzato
|
DC788KY
|
Estramustine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Fludarabine + Hepzato
|
DC58D25
|
Fludarabine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Fludarabine + Hepzato
|
DCCHA7J
|
Fludarabine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
FORMESTANE + Hepzato
|
DC39FMM
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
FORMESTANE + Hepzato
|
DCJPLAL
|
FORMESTANE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
FORMESTANE + Hepzato
|
DCEZ9F4
|
FORMESTANE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Fulvestrant + Hepzato
|
DC30Q34
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Fulvestrant + Hepzato
|
DC96SIG
|
Fulvestrant
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Fulvestrant + Hepzato
|
DCG3O4U
|
Fulvestrant
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Fulvestrant + Hepzato
|
DC9WXUK
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Gefitinib + Hepzato
|
DC3W302
|
Gefitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Gefitinib + Hepzato
|
DCZDGYE
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Gefitinib + Hepzato
|
DCUMS1E
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Hepzato + Pentostatin
|
DCQADI6
|
Pentostatin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Hepzato + Pentostatin
|
DCMB4TA
|
Pentostatin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Hepzato + Pentostatin
|
DCAVCMM
|
Pentostatin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Hepzato + Fulvestrant
|
DCW2ZY2
|
Fulvestrant
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Hepzato + Ixabepilone
|
DC4J4BN
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Hepzato + Ixabepilone
|
DC14AD1
|
Ixabepilone
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + Isoniazid
|
DCS28GU
|
Isoniazid
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Hepzato + Topetecan
|
DCFDCI3
|
Topetecan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Hepzato + Pralatrexate
|
DCFNRUF
|
Pralatrexate
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Hepzato + Terameprocol
|
DCUD1D2
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Hepzato + Terameprocol
|
DC6S3XJ
|
Terameprocol
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Hepzato + Terameprocol
|
DC7DHX3
|
Terameprocol
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Hepzato + Terameprocol
|
DC4XWNC
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Hepzato + Terameprocol
|
DCFBNEA
|
Terameprocol
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Hepzato + Terameprocol
|
DCK8IHH
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Hepzato + Terameprocol
|
DC74FIE
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Hepzato + Terameprocol
|
DCX12ZO
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Hepzato + Terameprocol
|
DCVMJY8
|
Terameprocol
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Hepzato + Terameprocol
|
DCL6PM8
|
Terameprocol
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Hepzato + Terameprocol
|
DC0HL1I
|
Terameprocol
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Hepzato + Terameprocol
|
DCLI4ZC
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + SCH 727965
|
DC12Y5W
|
SCH 727965
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Hepzato + Ifosfamide
|
DCMPL9G
|
Ifosfamide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Hepzato + Ifosfamide
|
DCOQZGW
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + Docetaxel
|
DC2BX6V
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Hepzato + Docetaxel
|
DC5GZU0
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Hepzato + Docetaxel
|
DCEJRSF
|
Docetaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Hepzato + Sirolimus
|
DCRT630
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Hepzato + Mitomycin
|
DCG2Y7J
|
Mitomycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Hepzato + Altretamine
|
DCZDCNS
|
Altretamine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Hepzato + Altretamine
|
DCXJY3D
|
Altretamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + TEM
|
DCXTN17
|
TEM
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Hepzato + TEM
|
DC2TA3A
|
TEM
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Hepzato + TEM
|
DCN17TL
|
TEM
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Hepzato + Sorafenib
|
DC00MST
|
Sorafenib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Hepzato + Sorafenib
|
DCF9F0K
|
Sorafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + ER819762
|
DC3AE0G
|
ER819762
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Hepzato + ER819762
|
DCJMUDT
|
ER819762
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Hepzato + ER819762
|
DC0096A
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + Mepacrine
|
DC445JV
|
Mepacrine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Hepzato + Mepacrine
|
DC14D95
|
Mepacrine
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Hepzato + Taxol
|
DCPBRV7
|
Taxol
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Hepzato + Taxol
|
DC80PVU
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Hepzato + PMID28870136-Compound-43
|
DCFWGID
|
PMID28870136-Compound-43
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Hepzato + FORMESTANE
|
DC5XHOH
|
FORMESTANE
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Hepzato + Dasatinib
|
DC0IAVX
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Hepzato + Dasatinib
|
DCPD15T
|
Dasatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Hepzato + Cyclophosphamide
|
DCBXQWO
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Hepzato + Isoniazid
|
DC6UBWF
|
Isoniazid
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Hepzato + Terameprocol
|
DCFCD95
|
Terameprocol
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Hepzato + Terameprocol
|
DCJAFQX
|
Terameprocol
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Hepzato + Terameprocol
|
DCHXDHA
|
Terameprocol
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Hepzato + Terameprocol
|
DCXSO0L
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Hepzato + SCH 727965
|
DCYWM1H
|
SCH 727965
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Hepzato + Docetaxel
|
DCWESJZ
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Hepzato + TEM
|
DCZ1CSG
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Hepzato + TEM
|
DCCBBXH
|
TEM
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Hepzato + ER819762
|
DCSL8O9
|
ER819762
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Hepzato + Pomalidomide
|
DCK5MTN
|
Pomalidomide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Hepzato + Mepacrine
|
DCKWHM0
|
Mepacrine
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Hepzato + PMID28870136-Compound-43
|
DCKOM02
|
PMID28870136-Compound-43
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Hepzato + Aminolevulinic Acid Hydrochloride
|
DCA9UL7
|
Aminolevulinic Acid Hydrochloride
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Hepzato + Pentostatin
|
DC8JS4N
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Hepzato + Pentostatin
|
DC6QUFG
|
Pentostatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Hepzato + Fulvestrant
|
DC9NWNI
|
Fulvestrant
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Hepzato + Ixabepilone
|
DC7XQDF
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Cyclophosphamide
|
DCBTDB9
|
Cyclophosphamide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + Cyclophosphamide
|
DCHR3XV
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Hepzato + Cyclophosphamide
|
DCK9A7U
|
Cyclophosphamide
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Hepzato + Isoniazid
|
DCQN42W
|
Isoniazid
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Hepzato + Isoniazid
|
DCK7R6Q
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Hepzato + Arsenic trioxide
|
DCI9JCM
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Hepzato + Arsenic trioxide
|
DCSCR66
|
Arsenic trioxide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Hepzato + Arsenic trioxide
|
DCWK6K9
|
Arsenic trioxide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Hepzato + 10-hydroxycamptothecin
|
DCY2MDL
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Pralatrexate
|
DCQ9U8X
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Hepzato + Pralatrexate
|
DCH92OX
|
Pralatrexate
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Hepzato + Terameprocol
|
DCRLWII
|
Terameprocol
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Hepzato + Terameprocol
|
DCAOI22
|
Terameprocol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Hepzato + Terameprocol
|
DC68ZAG
|
Terameprocol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Hepzato + Terameprocol
|
DCZ5PNP
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Terameprocol
|
DCOZG66
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Hepzato + Terameprocol
|
DCOSCEX
|
Terameprocol
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + Terameprocol
|
DCMHZN5
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + Terameprocol
|
DCO3U9J
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Hepzato + Terameprocol
|
DCH88QQ
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Hepzato + Terameprocol
|
DC7GGYG
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Hepzato + Terameprocol
|
DCGA0HM
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Hepzato + Terameprocol
|
DC4RH99
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Hepzato + Terameprocol
|
DC7QPNF
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Hepzato + Terameprocol
|
DCP7VOU
|
Terameprocol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Hepzato + Terameprocol
|
DC7ZBXV
|
Terameprocol
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Hepzato + Terameprocol
|
DCVEPHT
|
Terameprocol
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Hepzato + Ifosfamide
|
DC6UKK3
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Hepzato + Docetaxel
|
DCXN7N1
|
Docetaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Hepzato + Docetaxel
|
DCDZN9Z
|
Docetaxel
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Hepzato + Docetaxel
|
DC3LB7M
|
Docetaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Hepzato + Docetaxel
|
DC39ZBH
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Hepzato + Docetaxel
|
DCKDOHX
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Hepzato + Docetaxel
|
DC53VZY
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Docetaxel
|
DCG3PQO
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + Docetaxel
|
DCUBVTY
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Hepzato + Bendamustine hydrochloride
|
DCV0C97
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Hepzato + Sirolimus
|
DCYBFGY
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Sirolimus
|
DCIW07V
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Hepzato + Mitomycin
|
DCYH9NP
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Hepzato + Mitomycin
|
DCIY4S1
|
Mitomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Hepzato + Altretamine
|
DCI8LHI
|
Altretamine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Hepzato + Altretamine
|
DCPQW7D
|
Altretamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Altretamine
|
DCDJLK2
|
Altretamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + Altretamine
|
DCM52U7
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + Altretamine
|
DCPYLAI
|
Altretamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Hepzato + Altretamine
|
DCZ7GRB
|
Altretamine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Hepzato + TEM
|
DCF77QR
|
TEM
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Hepzato + TEM
|
DC3DB6L
|
TEM
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + TEM
|
DCGVE6T
|
TEM
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Hepzato + Bleomycin
|
DCLQAEF
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Hepzato + Chlorambucil
|
DC0JMER
|
Chlorambucil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Hepzato + Chlorambucil
|
DCG3899
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Chlorambucil
|
DCCHQEL
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Hepzato + Sorafenib
|
DCMPI7W
|
Sorafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Hepzato + Sorafenib
|
DCL25OM
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Hepzato + Sorafenib
|
DC1HQ7W
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Sorafenib
|
DCPGWHD
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Hepzato + ER819762
|
DCF1DRL
|
ER819762
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + ER819762
|
DCR87ML
|
ER819762
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Hepzato + Azacitidine
|
DCGSUQK
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Hepzato + Pomalidomide
|
DCCHTKD
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Hepzato + Pomalidomide
|
DC29O22
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Hepzato + Pomalidomide
|
DCOEIP9
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Hepzato + Mepacrine
|
DC6V8PH
|
Mepacrine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Hepzato + Mepacrine
|
DC101IB
|
Mepacrine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + Mepacrine
|
DC5MRHC
|
Mepacrine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + Mepacrine
|
DCTZDQ6
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Hepzato + Mepacrine
|
DCQXOD7
|
Mepacrine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Hepzato + Mepacrine
|
DCVRI70
|
Mepacrine
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DCHR577
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DC6KIMC
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DCV6U9T
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DC7UA4S
|
PMID28870136-Compound-43
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Hepzato + FORMESTANE
|
DCN3DRM
|
FORMESTANE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Hepzato + FORMESTANE
|
DCO3PR3
|
FORMESTANE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + FORMESTANE
|
DCUX3W9
|
FORMESTANE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + FORMESTANE
|
DC2WOP6
|
FORMESTANE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Hepzato + FORMESTANE
|
DCK18RJ
|
FORMESTANE
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Idarubicin + Hepzato
|
DCD52ZM
|
Idarubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Imatinib + Hepzato
|
DCXUSJ2
|
Imatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Indazole derivative 5 + Hepzato
|
DC837P2
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Indazole derivative 5 + Hepzato
|
DC4NK4W
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Indazole derivative 5 + Hepzato
|
DCY0F38
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCXLI4K
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCHGV5M
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCBOFN4
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCWX2JC
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DC5Y0IP
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCHSWIB
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCZMWMO
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCNNUUT
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
JNK-IN-8 + Hepzato
|
DC5LWL6
|
JNK-IN-8
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Lenalidomide + Hepzato
|
DCPKA09
|
Lenalidomide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Lenalidomide + Hepzato
|
DCW2EQH
|
Lenalidomide
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Lenalidomide + Hepzato
|
DCRN2XC
|
Lenalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Lenalidomide + Hepzato
|
DCQMM0T
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Lenalidomide + Hepzato
|
DC7PCMQ
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Lenalidomide + Hepzato
|
DCSH414
|
Lenalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Lenalidomide + Hepzato
|
DCNCMBS
|
Lenalidomide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Letrozole + Hepzato
|
DCHUMAA
|
Letrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Letrozole + Hepzato
|
DCI4ZPZ
|
Letrozole
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Letrozole + Hepzato
|
DCCHMRE
|
Letrozole
|
Glioma (Cell Line: SF-295)
|
[2] |
|
LIAROZOLE + Hepzato
|
DCWIKXW
|
LIAROZOLE
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
LIAROZOLE + Hepzato
|
DC2GVVK
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
LIAROZOLE + Hepzato
|
DCPOAYS
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Mechlorethamine + Hepzato
|
DCJENEJ
|
Mechlorethamine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Mechlorethamine + Hepzato
|
DC4SXP8
|
Mechlorethamine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Mechlorethamine + Hepzato
|
DCOPGU4
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Mechlorethamine + Hepzato
|
DCZH20J
|
Mechlorethamine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Methotrexate + Hepzato
|
DCDV2MP
|
Methotrexate
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Methotrexate + Hepzato
|
DC2IR9R
|
Methotrexate
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Nilotinib + Hepzato
|
DC4S5WQ
|
Nilotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Picoplatin + Hepzato
|
DCLRTBY
|
Picoplatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Picoplatin + Hepzato
|
DCNJ472
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Plicamycin + Hepzato
|
DC3L44V
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Plicamycin + Hepzato
|
DC24MUM
|
Plicamycin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Plicamycin + Hepzato
|
DCUHPXN
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Plicamycin + Hepzato
|
DC5HJKC
|
Plicamycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Plicamycin + Hepzato
|
DC2QELG
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Plicamycin + Hepzato
|
DCQJSYS
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Plicamycin + Hepzato
|
DC8YEFP
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Plicamycin + Hepzato
|
DCM1NQA
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Raloxifene + Hepzato
|
DCLDZDY
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Raloxifene + Hepzato
|
DCAVXRW
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Raloxifene + Hepzato
|
DC6Q336
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Raloxifene + Hepzato
|
DCR9SF8
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Raloxifene + Hepzato
|
DC8AUL3
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Raloxifene + Hepzato
|
DC18NZU
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Raloxifene + Hepzato
|
DCZM1JU
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Ruxolitinib + Hepzato
|
DCZD8RU
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Ruxolitinib + Hepzato
|
DC4PYW7
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Ruxolitinib + Hepzato
|
DCZ7JYX
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Ruxolitinib + Hepzato
|
DCTUD2U
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
SY-1425 + Hepzato
|
DCGMUOJ
|
SY-1425
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Hepzato
|
DC2VJ7T
|
SY-1425
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SY-1425 + Hepzato
|
DC4BELG
|
SY-1425
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Terameprocol + Hepzato
|
DCZJH4X
|
Terameprocol
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Terameprocol + Hepzato
|
DCX18VR
|
Terameprocol
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Terameprocol + Hepzato
|
DCA5K55
|
Terameprocol
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Terameprocol + Hepzato
|
DCO7ED3
|
Terameprocol
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Terameprocol + Hepzato
|
DCY48LA
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Thioguanine + Hepzato
|
DC15IJ3
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Thioguanine + Hepzato
|
DCVDQFH
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Thioguanine + Hepzato
|
DCVM8CM
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Thioguanine + Hepzato
|
DCQN45A
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Thioguanine + Hepzato
|
DCLWMBI
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Topotecan + Hepzato
|
DC23Q9V
|
Topotecan
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Topotecan + Hepzato
|
DC47SHB
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Topotecan + Hepzato
|
DCX9JW2
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Topotecan + Hepzato
|
DC6DFEF
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Topotecan + Hepzato
|
DC7H56D
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Hepzato
|
DCNEHVZ
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + Hepzato
|
DC25LNG
|
Topotecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Triapine + Hepzato
|
DC2FL9A
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Triapine + Hepzato
|
DC9JM0Q
|
Triapine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Triapine + Hepzato
|
DCOJ54M
|
Triapine
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Triapine + Hepzato
|
DC9YYR5
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Triapine + Hepzato
|
DCK0ICA
|
Triapine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Trifluridine + Hepzato
|
DC4F8X6
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Trifluridine + Hepzato
|
DC8E2VG
|
Trifluridine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Trifluridine + Hepzato
|
DCNY7N1
|
Trifluridine
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Uracil mustard + Hepzato
|
DCCGCYQ
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Uracil mustard + Hepzato
|
DCY8KG7
|
Uracil mustard
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Uracil mustard + Hepzato
|
DCYPXGR
|
Uracil mustard
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Uracil mustard + Hepzato
|
DC03GN0
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Valrubicin + Hepzato
|
DCIHR2J
|
Valrubicin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vandetanib + Hepzato
|
DCD4Z53
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vandetanib + Hepzato
|
DCNBF07
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vandetanib + Hepzato
|
DCU42TX
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vandetanib + Hepzato
|
DCU2R8N
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vandetanib + Hepzato
|
DCZLAGD
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Hepzato
|
DCM6EEB
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Hepzato
|
DC5MKEP
|
Vemurafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Hepzato
|
DCL49VC
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Hepzato
|
DCJ4QEG
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Hepzato
|
DC5HU3V
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vincristine + Hepzato
|
DC6WFJ3
|
Vincristine
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Vincristine + Hepzato
|
DCMEXVD
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Vincristine + Hepzato
|
DCJ9PL8
|
Vincristine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Vincristine + Hepzato
|
DCFHBPF
|
Vincristine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Vincristine + Hepzato
|
DC64KAM
|
Vincristine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vinflunine + Hepzato
|
DCASY1N
|
Vinflunine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Vinflunine + Hepzato
|
DCFLQAD
|
Vinflunine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vinflunine + Hepzato
|
DCLOPGX
|
Vinflunine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vinflunine + Hepzato
|
DCBFZHO
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vinflunine + Hepzato
|
DC9X6C6
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vismodegib + Hepzato
|
DCHI2FO
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vismodegib + Hepzato
|
DC4D8H1
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vismodegib + Hepzato
|
DCMJZS3
|
Vismodegib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vismodegib + Hepzato
|
DC00AT5
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vismodegib + Hepzato
|
DC9RU65
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vismodegib + Hepzato
|
DC2QW0Y
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vismodegib + Hepzato
|
DC7I6ZD
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
